Menü
You have to log in or sign up before you can proceed.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device
Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

British Columbia First Province to Cover Dexcom G6 Continuous Glucose Monitoring System for People With Type 1 and Type 2 Diabetes on Intensive Insulin Therapy
British Columbia First Province to Cover Dexcom G6 Continuous Glucose Monitoring System for People With Type 1 and Type 2 Diabetes on Intensive Insulin Therapy


Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), announced today that people with diabetes who are on intensive insulin therapy, age two years or older, may

Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome


Regulatory News:



Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announces that it has entered into an

Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders


Clovis Oncology, Inc. (NASDAQ:CLVS) (the “Company”) today announced partial results and the partial adjournment of its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). The Company

Quidel to Present Virtually at Raymond James Human Health Innovation Conference 2021
Quidel to Present Virtually at Raymond James Human Health Innovation Conference 2021


Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at

League and Humana Partner to Digitally Transform Healthcare Experience for Millions of Members: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
League and Humana Partner to Digitally Transform Healthcare Experience for Millions of Members


League, a technology-focused health company powering digital transformation in healthcare, and Humana Inc. (NYSE: HUM), a leading health and well-being company, today announced an agreement to

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nationshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200

Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis


Regulatory News:



Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced dosing of the first patient

CenterWell Senior Primary Care to Open Six Senior-Focused Care Centers in Atlanta: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
CenterWell Senior Primary Care to Open Six Senior-Focused Care Centers in Atlanta


CenterWell Senior Primary Care will open six new senior-focused primary care centers in metro Atlanta through 2022, marking the company’s debut in the Atlanta market, giving local seniors access to

Humana Names Carolyn Tandy Chief Inclusion and Diversity Officer
Humana Names Carolyn Tandy Chief Inclusion and Diversity Officer


Leading health and well-being company Humana Inc. (NYSE: HUM) has named Carolyn Tandy to the position of Senior Vice President and Chief Inclusion and Diversity Officer. Tandy will be responsible

IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced the appointment of

U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Olderhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older


Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease

Waters Sets New Standard in High Resolution Mass Spectrometry with SELECT SERIES Multi Reflecting Time-of-Flight Platform
Waters Sets New Standard in High Resolution Mass Spectrometry with SELECT SERIES Multi Reflecting Time-of-Flight Platform


Waters Corporation (NYSE:WAT) today introduced the Waters™ SELECT SERIES™ MRT, a high-resolution mass spectrometer that combines Multi Reflecting Time-of-Flight (MRT) technology with both enhanced

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs): https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that the Japan Patent Office

Independent Proxy Advisory Firms Recommend IMV Shareholders Vote for All Director Nominees at the Upcoming Annual General and Special Meeting: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
Independent Proxy Advisory Firms Recommend IMV Shareholders Vote for All Director Nominees at the Upcoming Annual General and Special Meeting


IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious

Valbiotis ernennt Sébastien Bessy, einen internationalen Experten für Consumer Healthcare, zum Chief Operating Marketing and Business Officer: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis ernennt Sébastien Bessy, einen internationalen Experten für Consumer Healthcare, zum Chief Operating Marketing and Business Officer


Valbiotis (FR0013254851 – ALVAL, PEA/SME-fähig) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von

Aurinia Announces Results of the 2021 Annual General Meeting: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Results of the 2021 Annual General Meeting


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual

NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021


Regulatory News:



NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to

Valbiotis Appoints Sébastien Bessy, International Expert in Consumer Healthcare, as Chief Operating Marketing and Business Officer: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis Appoints Sébastien Bessy, International Expert in Consumer Healthcare, as Chief Operating Marketing and Business Officer


Press release



Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic

Charles River Laboratories Announces Long-Term Solar Contract for North American Operations: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Announces Long-Term Solar Contract for North American Operations


Charles River Laboratories International, Inc. (NYSE: CRL) today announced a long-term solar energy contract to address the entirety of the Company’s North American electric power requirements with

Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented an analysis of its Phase 3 AURORA 1 study data at the European Renal Association – European Dialysis

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement